BOSTON--(BUSINESS WIRE)--Entrada Therapeutics, a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointment of Peter S. Kim, Ph.D., to its Board of Directors.

"Dr. Kim is a pioneering scientist with over 30 years of experience in both academia and the biopharmaceutical industry," stated Dipal Doshi, President and CEO of Entrada Therapeutics. "He has been recognized with countless honors, awards and appointments throughout the course of his career and we are extraordinarily fortunate to welcome him to our Board of Directors. Dr. Kim’s scientific and drug development expertise and experience will contribute to Entrada’s success in developing groundbreaking therapies."

Dr. Kim is currently the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University, Institute Scholar at Stanford ChEM-H and Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub. Dr. Kim was President of Merck Research Laboratories (MRL) from 2003 to 2013, where he oversaw Merck's global drug and vaccine research and development activities. During his tenure at MRL, Dr. Kim oversaw the approval of more than 20 new medicines and vaccines.

"Entrada's platform represents an elegant solution to a fundamental problem, which is that the efficacy of intracellular biologics depends upon efficient cellular uptake and escape from the early endosome," said Dr. Kim. "The team’s research, therefore, has the potential to revolutionize how we think about the accessibility of drug targets. I’ve joined Entrada’s Board because I believe the Company is well-positioned to develop novel therapeutics that may fundamentally change the standard-of-care in a wide range of diseases where there are currently no adequate therapies.”

Prior to his time at Merck, Dr. Kim was a Professor of Biology at Massachusetts Institute of Technology and a Member of the Whitehead Institute where he conducted seminal research elucidating the way in which proteins enable viral membranes to fuse with cells. Dr. Kim’s exceptional record of scientific achievement resulted in his election to the National Academy of Sciences, the National Academy of Medicine, the National Academy of Engineering, the American Academy of Arts and Sciences and the Korean Academy of Science and Technology. Dr. Kim is also a Fellow with the American Association for the Advancement of Science, the American Academy of Microbiology and the Biophysical Society.

"Not only is Dr. Kim an early pioneer and preeminent expert in the fields of membrane fusion and intracellular targeting, he also brings unmatched experience when it comes to taking groundbreaking products from bench to bedside," commented Kush Parmar, Chairman of Entrada’s Board of Directors. "Dr. Kim was one of the first people to recognize the potential of the EEVTM platform and on behalf of everyone at the Company I am very pleased to welcome him to our Board."

About Entrada Therapeutics

Entrada Therapeutics’ mission is to treat devastating diseases by developing intracellular biologics. Using its proprietary EEVTM platform, Entrada is creating a diverse pipeline of oligonucleotide, enzyme, protein and peptide programs to efficiently engage intracellular disease targets across multiple therapeutic areas. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the field of intracellular biologics. Entrada is backed by 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital. For more information, please visit www.entradatx.com.